Knocout PE: Retrospective and prospective international EKoSoNic(R) registry Of the treatment and Clinical OUTcomes of patients with Pulmonary Embolism

A clinical registry study is a collection of data from medical records, screening assessments and treatment procedure. You are being invited to participate, because you have a blood clot in one or both of the large blood vessels in your chest (lung arteries) that is interfering with blood flow through your heart and lungs. Your doctor has decided to use a clot-dissolving drug (thrombolytic drug) in combination with a commercially-available device, called the EkoSonic(R) Endovascular System (EKOS). The EKOS uses ultrasound energy (high-frequency sound waves) to make it easier for the drug to enter the clot which may reduce treatment time and the amount of drug needed to dissolve the clot. There will be up to 1550 participants in the United States, Europe and Asia who will join this Registry. Of that total number, about 550 participants will have not yet received the EKOS treatment. The remaining 1000 people will have already had EKOS treatment, so their participation will only involve collecting data from their medical records. Your participation in the Registry will last for 12 months (hospital time plus one year of follow-up). The study is being conducted for EKOS Corporation which is part of the BTG International group of companies. Your doctor is being paid by EKOS Corporation to conduct this Registry.

Scholars @ ECU